Heart Failure Therapy — Heart failure drug classes and guideline-directed therapy concepts

Heart failure has been recognized as a clinical syndrome for centuries, yet rational pharmacological therapy only emerged in the latter half of the twentieth century. For decades, the standard approach to managing congestive heart failure relied on bed rest, fluid restriction, and digitalis — a cardiac glycoside whose use dates back to William Withering's observations of foxglove in 1785. While digitalis improved symptoms and reduced hospitalizations, it did not meaningfully extend survival. The pathophysiological understanding of heart failure evolved from a purely hemodynamic model — the heart as a failing pump — toward a neurohormonal model in which maladaptive activation of the renin–angiotensin–aldosterone system (RAAS) and the sympathetic nervous system drives disease progression. This paradigm shift catalyzed the development of every modern heart failure drug class and underpins the concept of guideline-directed medical therapy (GDMT).

This historical arc poses the central question of modern heart failure pharmacology: how do we optimally combine neurohormonal blockade, natriuretic peptide augmentation, and glucosuric cardioprotection into a coherent regimen that maximizes survival benefit while minimizing adverse effects? The answer lies in understanding each drug class's mechanism of action and the framework of guideline-directed medical therapy.

Before exploring individual drug classes, it is essential to anchor the discussion in the foundational principles that govern heart failure therapy. Heart failure is classified by left ventricular ejection fraction (LVEF) into three categories: heart failure with reduced ejection fraction (HFrEF, LVEF ≤ 40%), heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41–49%), and heart failure with preserved ejection fraction (HFpEF, LVEF ≥ 50%). The robust evidence base for GDMT primarily applies to HFrEF, although recent trials have begun to demonstrate benefits of SGLT2 inhibitors in HFpEF. The neurohormonal model posits that after an initial cardiac insult, compensatory activation of the RAAS and the sympathetic nervous system temporarily preserves cardiac output but ultimately accelerates myocardial remodeling, fibrosis, and cell death — a vicious cycle that GDMT aims to interrupt at multiple points.

The diagram above illustrates why monotherapy is insufficient. Blocking only the RAAS (left branch) leaves the sympathetic nervous system unchecked, and vice versa. Furthermore, aldosterone escape — a phenomenon in which aldosterone levels rise despite ACE inhibitor therapy — necessitates the addition of an MRA. The SGLT2 inhibitors act through mechanisms that are still being fully elucidated, including osmotic diuresis, reduced preload, improved myocardial energetics, and anti-inflammatory effects that are partly independent of the classical neurohormonal axes. This complementarity is why contemporary guidelines recommend initiating all four pillars early and simultaneously titrating them to target doses.

Pillar 1: RAAS Inhibition — ACEi, ARB, and ARNI

ACE inhibitors (e.g., enalapril, lisinopril, ramipril) block the conversion of angiotensin I to angiotensin II by inhibiting angiotensin-converting enzyme. This reduces vasoconstriction, decreases aldosterone secretion, and lowers both preload and afterload. ACE also degrades bradykinin, so ACE inhibition leads to bradykinin accumulation — responsible for both the beneficial vasodilatory effects and the adverse effect of dry cough. Angiotensin receptor blockers (ARBs, e.g., losartan, valsartan) selectively block the AT₁ receptor, achieving RAAS inhibition without increasing bradykinin levels, making them the alternative for patients with ACE inhibitor–induced cough or angioedema.

The angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan combines AT₁ receptor blockade with inhibition of neprilysin, the enzyme that degrades natriuretic peptides (ANP, BNP, CNP). By preventing natriuretic peptide degradation, sacubitril augments vasodilation, natriuresis, and anti-fibrotic signaling. The PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced the composite of cardiovascular death or heart failure hospitalization by 20% compared with enalapril alone, establishing the ARNI as the preferred first-line agent in HFrEF when tolerated.

Pillar 2: Beta-Adrenergic Blockade

Three beta-blockers have proven mortality benefit in HFrEF: carvedilol (a non-selective β₁/β₂/α₁ blocker), metoprolol succinate (a selective β₁ blocker in extended-release form), and bisoprolol (a selective β₁ blocker). These agents counteract chronic sympathetic overdrive by reducing heart rate, myocardial oxygen consumption, and arrhythmia risk while promoting favorable ventricular remodeling. It is critical to initiate beta-blockers at low doses in compensated patients and up-titrate gradually over weeks; starting at target doses in an acutely decompensated patient can precipitate cardiogenic shock.

Pillar 3: Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone and eplerenone block aldosterone at the mineralocorticoid receptor, reducing sodium and water retention, myocardial fibrosis, and vascular inflammation. Spironolactone is non-selective and also binds androgen and progesterone receptors, which can cause gynecomastia and menstrual irregularities; eplerenone is selective for the mineralocorticoid receptor and has a more favorable side-effect profile. Both agents carry a risk of hyperkalemia, necessitating regular monitoring of serum potassium and renal function, particularly when combined with ACE inhibitors or ARBs.

Pillar 4: SGLT2 Inhibitors

The sodium–glucose cotransporter 2 (SGLT2) inhibitors — dapagliflozin and empagliflozin — were initially developed as antidiabetic drugs but have demonstrated robust cardiovascular benefits independent of glycemic control. By inhibiting SGLT2 in the proximal tubule, these agents promote glucosuria and natriuresis, reducing plasma volume and preload. Emerging evidence suggests additional mechanisms including improved myocardial energetics through enhanced ketone body utilization, reduced inflammation and oxidative stress, and beneficial effects on autophagy. The DAPA-HF and EMPEROR-Reduced trials showed approximately 25–26% reductions in the composite of worsening heart failure or cardiovascular death.

Notice in the diagram above that each pillar addresses a different pathophysiological axis: the ARNI handles RAAS inhibition and natriuretic peptide augmentation simultaneously; the beta-blocker counters sympathetic overdrive; the MRA addresses aldosterone escape and anti-fibrotic therapy; and the SGLT2 inhibitor provides hemodynamic unloading and metabolic optimization. The adjunctive therapies — loop diuretics, hydralazine/isosorbide dinitrate, ivabradine, and digoxin — serve specific clinical scenarios but do not replace the four pillars.

Consider a 58-year-old male presenting with dyspnea on exertion, bilateral lower extremity edema, and a chest radiograph showing cardiomegaly and pulmonary vascular congestion. Echocardiography reveals an LVEF of 28%, and his BNP is 1,200 pg/mL. His vitals are: BP 118/76 mmHg, HR 88 bpm, K⁺ 4.2 mEq/L, eGFR 55 mL/min/1.73 m². He has no history of diabetes. The following clinical reasoning exercise demonstrates how to build his GDMT regimen.

No pharmacological intervention is free of trade-offs. Each pillar of GDMT brings substantial mortality benefit but also carries risks that must be weighed against the clinical context. The following table summarizes key advantages and limitations for each drug class, providing a framework for clinical decision-making when patients present with contraindications or intolerances.

Beyond the four pillars of GDMT, the landscape of heart failure therapy continues to expand. Understanding the bridge from optimized medical therapy to advanced interventions — and appreciating where research is heading — is essential for any student of cardiovascular pharmacology. This section contrasts foundational GDMT concepts with their advanced extensions.

The trajectory of heart failure therapeutics is moving toward precision medicine: biomarker-guided titration (serial NT-proBNP monitoring), phenotype-specific therapy (HFpEF with obesity may respond to GLP-1 receptor agonists like semaglutide, as shown in STEP-HFpEF), and gene therapy for specific cardiomyopathies. Device-based therapies — including implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden cardiac death and cardiac resynchronization therapy (CRT) for patients with LBBB and LVEF ≤ 35% — remain integral complements to pharmacological GDMT. Students should recognize that GDMT is the foundation upon which all advanced therapies are built, and that a patient should generally be on optimized GDMT before considering device implantation or advanced surgical interventions.